AmyriAD Therapeutics has acquired Recognify to expand its cognition-focused development pipeline, highlighting continued investment in therapies targeting cognitive impairment and related neurological needs. The financial terms of the transaction were not disclosed.
AmyriAD Therapeutics is a biotechnology company focused on developing treatments for neurological and cognitive conditions, with a pipeline strategy that aims to address unmet needs in brain health and cognition. Recognify has focused on developing therapeutic approaches for cognitive impairment. Its assets and research capabilities will add to AmyriAD Therapeutics’s efforts in cognition-related drug development.
The acquisition strengthens AmyriAD Therapeutics’s cognition pipeline and expands its focus on cognitive-health research. The deal brings Recognify’s relevant assets and expertise into AmyriAD Therapeutics’s portfolio. Further development will determine the clinical and commercial potential of the combined pipeline.